Corporate Member Seattle Genetics - NEW Indication

Corporate Member Seattle Genetics - NEW Indication

ADCETRIS® (brentuximab vedotin)
April, 2018

New FDA-approved indication for ADCETRIS® (brentuximab vedotin) for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.  This approval was based on the results of the Phase 3 ECHELON-1 trial,  a multi-center, randomized, open-label, global, superiority trial of A+AVD (ADCETRIS + doxorubicin, vinblastine, dacarbazine) vs ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) in patients with newly diagnosed advanced-stage cHL. The ECHELON-1 trial enrolled 1,334 patients with Stage III or IV cHL and randomized patients 1:1 to receive up to 6 cycles of A+AVD or ABVD on Days 1 and 15 of each 28-day cycle.

Become a NOS Member Today!

Platinum Corporate Members

Gold Corporate Members